Protocol

Molecular Diagnostics for Melanoma

Volume 1102 of the series Methods in Molecular Biology pp 83-95

Date:

Markers for Anti-cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Therapy in Melanoma

  • Michael A. PostowAffiliated withDepartment of Medicine, Memorial Sloan-Kettering Cancer Center
  • , Jianda YuanAffiliated withDepartment of Medicine, Memorial Sloan-Kettering Cancer Center
  • , Shigehisa KitanoAffiliated withDepartment of Medicine, Memorial Sloan-Kettering Cancer Center
  • , Alexander M. LesokhinAffiliated withDepartment of Medicine, Memorial Sloan-Kettering Cancer Center
  • , Jedd D. WolchokAffiliated withDepartment of Medicine, Memorial Sloan-Kettering Cancer Center

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Therapeutic strategies that block Cytotoxic T lymphocyte antigen-4 (CTLA-4) enhance antitumor immunity and prolong the lives of patients with metastatic melanoma. However, only a subset of patients benefit, and responses are often delayed due to heterogeneous response kinetics. Ongoing monitoring of the immunologic effects of therapy and correlating these immunologic changes with patient outcomes continue to be important goals to better identify possible mechanisms of clinical activity of these agents. This chapter introduces the major areas of investigation in monitoring patients treated with CTLA-4 blockade and provides specific details of our experience performing selected assays.

Key words

Ipilimumab Tremelimumab CTLA-4 Immunologic response biomarkers Absolute lymphocyte count Inducible costimulator Myeloid-derived suppressor cells NY-ESO-1 antigen